Evaluation of the KIT/stem cell factor axis in renal tumours

Anticancer Research

Volumn 32, Issue 10, 2012, Pages 4339-4346

  Horstmann, Markus ^a,c   Hennenlotter, Joerg ^a   Geiger, Lisa M ^a   Vogel, Ulrich ^b   Schmid, Heidi ^a   Kuehs, Ursula ^a   Stenzl, Arnulf ^a   Bedke, Jens ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c University of Tuebingen ^*  (Switzerland)

Author keywords

Imatinib; KIT; Oncocytoma; Renal cell carcinoma; Stem cell factor; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

STEM CELL FACTOR;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SIZE; CANCER STAGING; CLEAR CELL CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY DISTAL TUBULE; KIDNEY PROXIMAL TUBULE; MAJOR CLINICAL STUDY; MALE; ONCOCYTOMA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOMA, OXYPHILIC; AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-KIT; STEM CELL FACTOR;

EID: 84867773542     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Ferlay J, Parkin D and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4): 765-781, 2010.
2. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U and Ullrich A: Human proto-oncogene c-KIT: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6(11): 3341-3351, 1987.
3. Geissler EN, Liao M, Brook JD, Martin FH, Zsebo KM, Housman DE and Galli SJ: Stem cell factor (SCF), a novel hematopoietic growth factor and ligand for c-KIT tyrosine kinase receptor, maps on human chromosome 12 between 12q14.3 and 12qter. Somat Cell Mol Genet 17(2): 207-214, 1991.
4. Malaise M, Steinbach D and Corbacioglu S: Clinical implications of c-KIT mutations in acute myelogenous leukemia. Curr Hematol Malign Rep 4(2): 77-82, 2009.
5. Ray P, Krishnamoorthy N and Ray A: Emerging functions of c-KIT and its ligand stem cell factor in dendritic cells: Regulators of T cell differentiation. Cell cycle 7(18): 2826-2832, 2008.
6. Lev S, Blechman JM, Givol D and Yarden Y: Steel factor and c-KIT protooncogene: genetic lessons in signal transduction. Crit Rev in Oncogen 5(2-3): 141-168, 1994.
7. Mauduit C, Hamamah S and Benahmed M: Stem cell factor/c-KIT system in spermatogenesis. Hum Reprod Update 5(5): 535-545, 1999. (Pubitemid 29512140)
8. van Dijk TB, van Den Akker E, Amelsvoort MP, Mano H, Lowenberg B and von Lindern M: Stem cell factor induces phosphatidylinositol 3'-kinase-dependent Lyn/Tec/Dok-1 complex formation in hematopoietic cells. Blood 96(10): 3406-3413, 2000.
9. Stoop H, Honecker F, van de Geijn GJ, Gillis AJ, Cools MC, de Boer M, Bokemeyer C, Wolffenbuttel KP, Drop SL, de Krijger RR, Dennis N, Summersgill B, McIntyre A, Shipley J, Oosterhuis JW and Looijenga, L H: Stem cell factor as a novel diagnostic marker for early malignant germ cells. J Pathol 216(1): 43-54, 2008.
10. Levina V, Marrangoni A, Wang T, Parikh S, Su Y, Herberman R, Lokshin A and Gorelik E: Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-KIT autocrine signaling loop. Cancer Res 70(1): 338-346, 2010.
11. Smithey BE, Pappo AS and Hill DA: C-KIT expression in pediatric solid tumors: a comparative immunohistochemical study. Am J Surg Pathol 26(4): 486-492, 2002. (Pubitemid 34280122)
12. Ricotti E, Fagioli F, Garelli E, Linari C, Crescenzio N, Horenstein AL, Pistamiglio P, Vai S, Berger M, di Montezemolo LC, Madon E and Basso G: c-KIT is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells. Blood 91(7): 2397-2405, 1998. (Pubitemid 28155514)
13. Lennartsson J and Ronnstrand L: The stem cell factor receptor/c-KIT as a drug target in cancer. Current cancer drug targets 6(1): 65-75, 2006.
14. Masson K and Ronnstrand L: Oncogenic signaling from the hematopoietic growth factor receptors c-KIT and Flt3. Cellular signalling 21(12): 1717-1726, 2009.
15. Huo L, Sugimura J, Tretiakova MS, Patton KT, Gupta R, Popov B, Laskin WB, Yeldandi A, Teh BT and Yang XJ: C-KIT expression in renal oncocytomas and chromophobe renal cell carcinomas. Hum Pathol 36(3): 262-268, 2005. (Pubitemid 40404009)
16. Kruger S, Sotlar K, Kausch I and Horny HP: Expression of KIT (CD117) in renal cell carcinoma and renal oncocytoma. Oncology 68(2-3): 269-275, 2005. (Pubitemid 41158986)
17. Pan CC, Chen PC and Chiang H: Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol 121(6): 878-883, 2004. (Pubitemid 38669283)
18. Petit A, Castillo M, Santos M, Mellado B, Alcover JB and Mallofre C: KIT expression in chromophobe renal cell carcinoma: comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms. Am J Surg Pathol 28(5): 676-678, 2004. (Pubitemid 38579572)
19. El-Koraie AF, Baddour NM, Adam AG, El Kashef EH and El Nahas AM: Role of stem cell factor and mast cells in the progression of chronic glomerulonephritides. Kidney Int 60(1): 167-172, 2001. (Pubitemid 32587551)
20. Yamazaki K, Sakamoto M, Ohta T, Kanai Y, Ohki M and Hirohashi S: Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 22(6): 847-852, 2003. (Pubitemid 36255820)
21. Lopez-Beltran A, Scarpelli M, Montironi R and Kirkalli Z: 2004 WHO classification of the renal tumors in adults. Eur Urol 49(5): 798-805, 2006.
22. Sobin LH: TNM Classification of Malignant Tumours (UICC), Wiley, 6 th Edition. New York; 2002.
23. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G and Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7): 844-847, 1998. (Pubitemid 28331029)
24. Kramer MW, Merseburger AS, Hennenlotter J and Kuczyk M: Tissue microarrays in clinical urology-technical considerations. Scand J Urol Nephrol 41(6): 478-484, 2007. (Pubitemid 350207539)
25. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8(3): 138-140, 1987.
26. Miliaras D, Karasavvidou F, Papanikolaou A and Sioutopoulou D: KIT expression in fetal, normal adult, and neoplastic renal tissues. J Clin Pathol 57(5): 463-466, 2004. (Pubitemid 38621789)
27. Ahmed EA and Youssif ME: Immunohistochemical study of c-KIT (CD117) expression in renal cell carcinoma. J Egypt Nat Cancer Insti 21(2): 121-132, 2009.
28. Lennartsson J, Jelacic T, Linnekin D and Shivakrupa R: Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem cells 23(1): 16-43, 2005. (Pubitemid 40105289)
29. Easty DJ and Bennett DC: Protein tyrosine kinases in malignant melanoma. Melanoma Res 10(5): 401-411, 2000.
30. Gutman M, Singh RK, Radinsky R and Bar-Eli M: Intertumoral heterogeneity of receptor-tyrosine kinases expression in human melanoma cell lines with different metastatic capabilities. Anticancer Res 4(5A): 1759-1765, 1994.
31. Lengyel E, Sawada K and Salgia R: Tyrosine kinase mutations in human cancer. Current molecular medicine 7(1): 77-84, 2007. (Pubitemid 46322280)
32. Petit A, Castillo M, Mellado B and Mallofre C: c-KIT overexpression in chromophobe renal cell carcinoma is not associated with c-KIT mutation of exons 9 and 11. Am J Surg Pathol 29(11): 1544-1545, 2005. (Pubitemid 41513309)
33. Terada T: Protein expression and gene mutation status of KIT and PDGFRA in renal cell carcinoma. Histol and Histopathol 27(3): 297-302, 2012.
34. Lin ZH, Han EM, Lee ES, Kim CW, Kim HK, Kim I and Kim YS: A distinct expression pattern and point mutation of c-KIT in papillary renal cell carcinomas. Mod Pathol 17(6): 611-616, 2004. (Pubitemid 38715481)
35. Kruck S, Kuczyk MA, Gakis G, Kramer MW, Stenzl A and Merseburger AS: Novel therapeutic options in metastatic renal cancer - review and post ASCO 2007 update. Rev Rec Clin Trials 3(3): 212-216, 2008.
36. Amato RJ, Jac J and Hernandez-McClain J: Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial. Anticancer Drugs 19(5): 527-533, 2008. (Pubitemid 351556404)
37. Vuky J, Isacson C, Fotoohi M, dela Cruz J, Otero H, Picozzi V, Malpass T, Aboulafia D and Jacobs A: Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma. Investig New Drugs 24(1): 85-88, 2006. (Pubitemid 43163424)
38. Sonpavde G, Hutson TE and Sternberg CN: Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin Investig Drugs 17(2): 253-261, 2008. (Pubitemid 351578205)
39. Choueri T, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini B, Bukowski R and Escudier B: Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26(1): 127-131, 2008.